Regeneron warned its popular antibody cocktail used to treat high-risk cases of COVID-19 may not be as effective against the new Omicron variant. The New York-based pharmaceutical company said ...

A single dose of Regeneron’s antibody cocktail—administered via four injections—cut the risk of contracting Covid-19 by 81.6% up to eight months after it’s given, the New York-based ...

Regeneron Pharmaceuticals and AstraZeneca, makers of monoclonal antibody cocktails used as treatment for many coronavirus patients who have not been vaccinated, announced contrasting data Thursday ...

Biotech giant Regeneron has claimed that its antibody cocktail reduces the risk of COVID-19 infection by nearly 82% for eight months.

An expert WHO panel recommended Regeneron’s antibody cocktail (marketed as REGEN-COV in the U.S.) for patients at risk of developing severe Covid-19 and patients with severe or critical Covid-19 ...

Regeneron Pharmaceuticals said Tuesday that its antibody cocktail, which is used widely to treat COVID-19 patients, may be less effective against the Omicron variant.

Regeneron’s antibody cocktail cut the risk of contracting COVID-19 by 81.6 percent in the two to eight months after the cocktail’s administration, the pharmaceutical company announced on Monday.

There hasn’t been any direct data testing yet to evaluate the omicron variant’s resistance to coronavirus cocktails and vaccines, but Regeneron wants to start studying the latest variant. The ...

TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ --EC marketing authorization follows approvals in Japan, Australia and the UKRegeneron Pharmaceuticals ...

Shares of Regeneron Pharmaceuticals Inc. gained 3.7% in premarket trading on Monday after the company said four subcutaneous injections of its monoclonal antibody treatment protected unvaccinated ...

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period ...

Regeneron Pharmaceuticals REGN’s antibody cocktail for COVID-19, REGEN-COV (casirivimab and imdevimab) is now being recommended for treatment by the Governor of Florida as cases continue to surge.